Target- |
MechanismStem cell replacements |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I Single-arm, Open-label Prospective Study to Evaluate the Efficacy and Safety of Peripheral Blood Derived Autologous Multi-lineage Potential Cells (AMPC) in Relapsed/Refractory Acute Myeloid Leukemia (AMPCAL Study)
A private trial for evaluating the overall response rate contributed by AMPC in AML in refractory or relapsed AML
100 Clinical Results associated with Lai Fung Holdings Ltd.
0 Patents (Medical) associated with Lai Fung Holdings Ltd.
100 Deals associated with Lai Fung Holdings Ltd.
100 Translational Medicine associated with Lai Fung Holdings Ltd.